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Abstract
Vitamin D is a kind of steroid hormone and is well known for its important role in regu‐
lating the levels of calcium (Ca) and phosphorus (P) as well as in mineralization of bone 
in body. But the vitamin D signaling also exhibits multiple effects, such as anti‐inflam‐
mation effects, anticancer effect, and cardiovascular‐ and kidney‐protective effects. From 
a practical point of view, vitamin D deficiency participates in many pathological pro‐
gressions and diseases. In some diseases, the administration of vitamin D or vitamin D 
receptor agonist (VDRA) could rescue the clinical symptoms and improve outcomes. In 
this review, we briefly deal with these topics, limiting ourselves to comment on some 
novelty studies about vitamin D signaling, which might help us to understand the mul‐
tiple effects of vitamin D in some pathological progresses and diseases, which are all 
worth to be studied further.
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1. Introduction
Vitamin D is a kind of steroid hormone and presents naturally in very few foods. However, 
a number of foods have been fortified and sun exposure produces vitamin D in the skin. The 
final hormonal form of vitamin D was generated by undergoing two hydroxylation steps, the 
first to produce 25(OH)D3 in the liver and then second in the kidney to create the hormonal 
form, 1,25(OH)2D3, after consumed or made in the skin.
Vitamin D has been known for its important role in regulating the levels of calcium (Ca) and 
phosphorus (P) as well as in mineralization of bone in the body. But vitamin D deficiency has 
become a major health problem worldwide, which was thought to be related with several fac‐
tors according to many researches, such as gender, age, sunlight exposure, cultures, dietary, 
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and so on. In 2012, the 25(OH)D of 2327 (1744 females and 583 males) healthy Caucasian outpa‐
tients were tested in the North‐East of Italy. The results showed that the 25(OH)D values had no 
significant differences between females and males. A nonsignificant variation of 25(OH)D val‐
ues was also found throughout four age cohorts (<21, 21–40, 41–60, and >60 years), in both gen‐
ders. In each age group, the values of 25(OH)D did not significantly differ between genders [1].
But in 2016, a single‐center analysis of patients from 136 countries showed that 82.5% of the 
studied patients (57.5% were female and 42.5% were male) have vitamin D deficiency to insuf‐
ficiency; 26.4% of females and 18.4% of males have extreme deficiency of 25(OH)D. There was 
higher variability of vitamin D in the group of females than males according to coefficient of 
variation. The prevalence of hypovitaminosis D is significantly high among population of 
UAE, Saudi Arabia, and many Middle Eastern countries, especially among women, despite 
abundant sunshine. This study considered the difference between female and male [2].
Vitamin D deficiency also existed in Europe. According to an alternate suggested definition of 
vitamin D deficiency (<50 nmol/L), the prevalence was 40.4%. Dark‐skinned ethnic subgroups 
had much higher (3‐ to 71‐fold) prevalence of serum 25(OH)D <30 nmol/L than did white 
populations [3]. In Sweden, about 56.4% people, 25‐OHD, were under 50 nmol/L, which was 
related to several unfavorable health outcomes [4].
Disorders in mineral metabolism and bone disease are common complications of chronic 
kidney disease (CKD). In 2009, the board of directors of kidney disease, improving global 
outcomes (KDIGO), published a new guideline for the treatment of patients of CKD and 
CKD‐related mineral and bone disorders (CKD‐MBD). The levels of 25(OH)D (calcidiol) were 
suggested to be measured and repeated testing determined by baseline values and interven‐
tions in patients with CKD stages 3–5 with CKD–MBD or CKD stages 1–5. And vitamin D 
deficiency and insufficiency should be corrected by using treatment strategies recommended 
in the general population [5].
However, an increasing amount of data has suggested a possible involvement of vitamin D 
activity in a great number of different pathophysiological fields not exclusively associated 
with mineral metabolism, such as modulation of inflammation and immune response, cell 
proliferation and differentiation, gene expression, and so on [6]. The functions of vitamin D 
have been widely found to be dependent not only on a widespread ability of different tissues 
to synthesize the active form of vitamin D but also on the almost ubiquitous distribution of 
the specific vitamin D receptor (VDR), which then translocates to the nuclei of target cells. In 
this review, we briefly deal with these topics, limiting ourselves to comment on some novelty 
studies about vitamin D signaling, which might help us to understand the multiple effects of 
vitamin D in some pathological progresses and diseases.
2. The effects of vitamin D
2.1. The effects of vitamin D in inflammation and immune response
Inflammation and immune response are the body's immediate responses to damage to its 
tissues and cells by pathogens, noxious stimuli such as chemicals, or physical injury. Recent 
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studies have suggested that vitamin D signaling played critical roles in controlling inflamma‐
tion and immune responses [7–9].
Immune cells such as activated CD8 (highest concentration), CD4 lymphocytes, and mac‐
rophages express VDR [10], which indicated that vitamin D signaling takes part in these 
cells‘functional modulation [11]. Vitamin D signaling potently inhibited antigen‐ and mito‐
gen‐induced T‐cell proliferation and cytokine production. Several key cytokines in T cells are 
direct targets of vitamin D signaling, in particular Th1 cytokines, such as IL‐2 (interleukin‐2) 
and IFN‐g (interferon‐gamma). Active vitamin D inhibits IL‐2 secretion via impairment of 
transcription factor NF‐AT (nuclear factor of activated T cells) complex formation, because the 
ligand‐bound VDR complex itself binds to the distal NF‐AT‐binding site of the human IL‐2 
promoter. IFN‐g has been found to be directly inhibited by vitamin D through interaction of 
the ligand‐bound VDR complex with a VDRE (vitamin D‐responsive element) in the promoter 
region of this cytokine [12]. In 2016, it was reported that 1α,25(OH)2 vitamin D3 modulates 
avian T lymphocyte functions without inducing cytotoxic T lymphocyte (CTL) unresponsive‐
ness [13]. Another study, a cross‐sectional study was from the National Health and Nutrition 
Examination Survey (NHANES) 2003–2006, showed sexually active women with cervicovagi‐
nal human papillomavirus (HPV) infection status and serum 25‐hydroxyvitamin D (25(OH)
D) levels (ng/mL) (n = 2353). Associations between serum 25(OH)D levels (continuous and 
categorical forms) and cervicovaginal HPV infection (high‐risk HPV or vaccine‐type HPV) 
were estimated using weighted logistic regression. The results showed that cervicovaginal 
HPV prevalence is associated with less‐than‐optimal levels of serum vitamin D [14].
Besides these, there are still some critical proteins through which vitamin D plays the modula‐
tion effect in inflammation and immune responses.
2.1.1. Toll‐like receptor‐9
The Toll‐like receptor 9 (TLR9) expression could be downregulated by vitamin D in monocytes. 
In response to decreased TLR9, these cells subsequently secreted less IL‐6 as a downstream 
functional effect. This phenomenon may have significant biological relevance and maybe a fac‐
tor in the association of vitamin D deficiency with susceptibility to autoimmune disease [15].
2.1.2. Nuclear factor kappa‐B
The antagonism between VDR and NF‐кB is mutual since overexpression of p65 but not p50 
subunit of NF‐кB inhibited VDRE‐mediated transcription in transfected cells. Similar NF‐кB‐
dependent mechanism has also been implicated in the inhibition of IL‐8 promoter expression 
by vitamin D signaling [16].
2.1.3. Tumor necrosis factor‐α
Tumor necrosis factor‐alpha (TNF‐α) is a pleiotropic inflammatory cytokine produced by 
activated immune cells as well as stromal cells. It was also reported that vitamin D inhibits 
TNF‐α in mycobacteria‐infected macrophages and peripheral blood mononuclear cells from 
pulmonary tuberculosis patients. The vitamin D analog cholecalciferol reduces the circulating 
level of TNF‐α in patients with ESRD (end‐stage renal disease) [17].
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Vitamin D signaling also inhibited the induced production of pro‐inflammatory cytokines, 
IL‐1α, IL‐6, and IL17 [18]. These activities form the basis of vitamin D‐mediated modulation 
of immune responses and inflammation.
2.2. The effect of vitamin D in cell proliferation and differentiation
Vitamin D has been demonstrated to alter cellular proliferation through multiple mechanisms 
in highly cell‐specific manners. One of the most important mechanisms was the slowing of 
cell cycle progression induced by vitamin D, typically due to inhibition of advancement from 
the G1 to the S phase of the cell cycle. Many key regulators, which influence gene transcrip‐
tion and protein stability, including p21waf1, p27kip1, cyclin D1, and others, are taken effect 
on by vitamin D. The ligand‐activated VDR directly or indirectly influences the cell cycle, 
apoptosis, and/or differentiation by interacting with important transcriptional regulators or 
cell‐signaling systems [19, 20].
Anti‐proliferative effects of vitamin D signaling are often, but not always, linked to the pro‐
motion of cellular differentiation. Vitamin D and the VDR also have important interactions 
with other transcriptional regulators and cell‐signaling systems. In many cell lines includ‐
ing cancer cells, 1,25(OH)2D3 and vitamin D analogs upregulate the expressions of TGF‐β receptor type I protein or androgen receptors, and downregulate the expressions of estrogen 
receptors or IGF (insulin‐like growth factor I). Vitamin D analogs also induce the expression 
of E‐cadherin, promoting translocation of β‐catenin from the nucleus to the cell membrane, to 
control cell growth and differentiation [19]. In our study, we found that VDR could be down‐
regulated by high glucose and take part in the epithelial‐epithelial‐mesenchymal transition of 
podocyte in mice [21].
3. Vitamin D and diseases
3.1. Vitamin D and kidney diseases
Kidney is the major site of the synthesis of 1, 25‐(OH)2D3, the active form of vitamin D, under physiologic conditions. Additionally, the vitamin D receptor, which binds to, and mediates 
the activity of 1, 25‐(OH)2D3, is widely distributed in the kidney. Thus, the kidney is essential 
not only for the maintenance of normal calcium and phosphorus homeostasis but also for the 
activation of vitamin D. There is close relationship among vitamin D, VDR, and the kidney. 
Any problem of kidney may lead to the vitamin D‐signaling deficiency, and vitamin D‐signal‐
ing deficiency always causes the abnormal function of kidney [22].
3.1.1. Chronic kidney disease
It was reported that when the glomerular filtration rate declines below 60 mL/min, chronic 
kidney disease (CKD) was always associated with increased cardiovascular events and 
mortality. One of the most important reasons was that the reduction/absence of kidney α1‐
hydroxylase, which mediates the final hydroxylation step of 25(OH)D to 1,25‐(OH)2D, could lead to the vitamin D deficiency in CKD patients. Vitamin D deficiency causes parathyroid 
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hyperplasia and increased parathyroid hormone; the consequent hyperparathyroidism 
and hyper‐phosphatemia are important risk factors for mortality in CKD patients [23, 24]. 
Accordingly, vitamin D treatment is associated with a reduced rate of cardiovascular diseases 
(CVDs) and mortality [25].
It has been shown that calcitriol (the active form of vitamin D) decreases the glomeruloscle‐
rosis index and albumin excretion in subtotally nephrectomized rats (SNX rats). Those mice 
lacking the VDR were more susceptible to hyperglycemia‐induced renal injury [26], which 
may be related to podocyte loss. And the scientists also found that the expression of renin 
could be inhibited by calcitriol, and a larger decrease in renal glomerulosclerosis in experi‐
mental CKD could be found for the combination use of enalapril and paricalcitol (VDR ago‐
nist, VDRA), which may be because of the decreased TGF‐β expression and macrophage 
infiltration [27].
In CKD patients treated with paricalcitol, proteinuria decreased after 23 weeks, indepen‐
dently of glomerular filtration rate, blood pressure, or angiotensin‐converting enzyme (ACE) 
inhibitor [28].
3.1.2. Diabetic nephropathy
Diabetic nephropathy (DN) is the most common renal complication of diabetes mellitus and a 
leading cause of end‐stage renal disease (ESRD). Intervention of DN remains a medical chal‐
lenge despite some success.
In recent years, renin‐angiotensin system (RAS) inhibitors have been used as the mainstay 
treatment for DN because the renin‐angiotensin system (RAS) was considered as a major 
mediator of progressive renal injury in DN. But the compensatory renin increase caused by 
the disruption of renin feedback inhibition becomes one major problem which limit the effi‐
cacy use of the RAS inhibitors. These most recent data demonstrate that vitamin D and its 
analogs have renoprotective and therapeutic potentials in DN through targeting the RAS. 
Vitamin D negatively regulates the RAS by suppressing renin expression and thus plays a 
renoprotective role in DN [26, 29]. The molecular mechanism underlying this regulation is that 
1,25(OH)2D3 disrupted the cAMP‐signaling pathway, a major regulatory pathway involved 
in renin biosynthesis [30]. It was reported that vitamin D analog therapy could increase long‐
term survival, reduces heart and kidney weights, and prevents overt renal tissue damage in 
mouse models. Combination therapy with a RAS inhibitor and a vitamin D analog was found 
to markedly improve renal injuries in the diabetic vitamin D receptor null‐mutant mice which 
developed more severe renal injuries because of more robust RAS activation [30]. Another 
study found that combined therapy with losartan and paricalcitol completely reduced pro‐
teinuria in a model of experimental diabetic nephropathy, suggesting that the combination 
of an ACE inhibitor or an ANG II receptor blocker plus a VDRA may be a good therapeutic 
option [23, 24].
Results from two clinical trials have provided some initial insight into the benefit of vita‐
min D therapy in diabetic nephropathy patients. Selective vitamin D receptor activation with 
paricalcitol for the reduction of albuminuria in patients with type 2 diabetes (VITAL study) 
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investigated an active vitamin D analog exclusively in diabetic nephropathy patients. These 
patients were all the type 2 diabetics with a stable dose of angiotensin‐converting enzyme 
(ACE) inhibitors or angiotensin receptor blockers (ARBs). The 281 patients were randomized 
into three groups: a single dose of placebo, 1 μg paricalcitol or 2 μg paricalcitol each day in 
a double‐blind fashion. After 4 months of treatment, a significantly greater reduction in 24‐h 
albumin excretion (measured by percent change from baseline) was found in the 2‐μg pari‐
calcitol group compared to placebo patients [31]. The second study about the measurement 
of the impact of vitamin D repletion with cholecalciferol on urinary albumin, MCP‐1, and 
TGF‐β1 was recently published by Kim and colleagues measured [32].
3.1.3. Immunoglobulin A nephropathy
The renoprotective effect of vitamin D was also investigated in immunoglobulin A (IgA) 
nephropathy. An open‐label, non‐placebo‐controlled, randomized study about the effect of 
vitamin D and urinary protein excretion in 50 IgA nephropathy patients was operated on 
by using calcitriol. Patients who receive two doses (0.5 mg) of calcitriol per week or no treat‐
ment for 48 weeks were randomly assigned (1:1). The urinary protein excretion >0.8 g/d after 
renin‐angiotensin system‐inhibitor treatment for at least 3 months was considered as the main 
criterion for inclusion. The changes of 24‐h urinary protein excretion from baseline to last 
measurement during treatment were compared and considered as the primary end point. 
The results showed that there was a significant decrease in proteinuria in the calcitriol‐treated 
group compared with the control group (difference between groups, 41%; 95% confidence 
interval (CI), 5–79%; P = 0.03) the primary end point. At least a 15% decrease in proteinuria 
was set as the secondary end point. And the result were 7 of 24 (29%) controls and 17 of 26 
(65%) of those treated with calcitriol (P = 0.02). These two groups showed the similar inci‐
dence of recorded adverse events, but had no significant differences in the decrease of esti‐
mated glomerular filtration rate and change in blood pressure. The conclusion was that the 
addition of calcitriol to a renin‐angiotensin system inhibitor resulted in a safe decrease in 
proteinuria in patients with IgA nephropathy [33].
3.1.4. Other renal diseases
Vitamin D also play renoprotective role in other renal diseases. For example, cholecalcif‐
erol (vitamin D analog) treatment significantly increased serum 25‐hydroxy vitamin D and 
decreased parathyroid hormone levels with no adverse effects in 25‐hydroxy vitamin D‐defi‐
cient renal‐transplant patients [34]. Vitamin D receptor agonist doxercalciferol modulates 
dietary fat‐induced renal disease and renal lipid metabolism [35].
Most of these studies have been reviewed recently and support the idea that vitamin D has 
therapeutic potential in slowing the progression of nephropathy. But these researches have 
their own limitations. The protection and mechanism of vitamin D need further study.
3.2. Vitamin D and cardiovascular disease
Cardiovascular disease (CVD) is the leading cause of death among patients with chronic 
kidney disease, with left ventricular hypertrophy (LVH) being a strong, independent risk 
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factor. LVH is also a major risk factor for coronary ischemia, congestive heart failure, and 
cardiac arrhythmias [24].
There is a growing body of evidence linking vitamin D signaling and CVD in both experi‐
mental animals and humans. For instance, animals lacking the VDR or having vitamin D 
deficiency always show cardiovascular abnormalities, such as hypertension and LVH [36]. 
Cardiomyocytes isolated from VDR knockout mice developed contractile abnormalities, such 
as accelerated contraction and relaxation rates [37]. In humans, studies found that vitamin 
D deficiency is prevalent in neonates with congenital cardiac defects, and lower postopera‐
tive 25(OH)D levels are associated with the need for increased inotropic support in neonates 
undergoing cardiac operations. Low serum 25(OH)D level could also increase the incidence 
of sudden cardiac death both in healthy people and in hemodialysis patients. Some research 
showed that vitamin D deficiency may play a role in myocardial injury and postoperative 
recovery. Furthermore, two studies demonstrated that individuals with lower levels of active 
vitamin D were at a higher risk of developing hypertension [38, 39]. Vitamin D also was 
found to modulate the growth, hypertrophy, and differentiation of cardiomyocytes, point‐
ing to a direct role for VDR agonists (VDRA) in cardiac physiology. These findings support 
that vitamin D deficiency is associated with poor cardiovascular outcomes in experimental 
animals and humans.
There were some reports about the improved cardiac function, which could be found in 
experimental animals or patients with administration of vitamin D or VDRAs. For example, 
after the treatment of paricalcitol, hypertensive rats showed a prevention of LVH and LV 
dysfunction accompanied with lower levels of brain natriuretic peptide and atrial natriuretic 
factor. VDRA therapy revealed similar results in another experimental model of LVH, the Cp/
rat model. Moreover, vitamin D is able to modulate contractility of cardiomyocytes in vitro by 
changing the distribution of the myosin chains and modulating Ca entry into cardiac muscle 
cells. In patients, the use of VDRA has been associated with improvements in left ventricular 
function and reductions in LVH [24].
Results from interventional trials, using either nutritional vitamin D or VDR agonists, sup‐
ported the idea that VDR activation was beneficial for improving the underlying factors of 
CVD such as hypertension, endothelial dysfunction, atherosclerosis, vascular calcification, 
and cardiac hypertrophy.
3.3. Vitamin D and inflammatory bowel disease
Immune‐mediated diseases such as inflammatory bowel diseases (IBDs) have increased 
in developed countries over the last 50 years. Scientists did much research to explain the 
increased incidence of IBD. They found that changing vitamin D status especially in prenatal 
as well as childhood could affect the development of the resultant immune response and the 
development of IBD.
There are reasons to believe that vitamin D could be an external factor that may play a role in 
the development of IBD. Animal models of experimental IBD had been used to explore the rela‐
tionship between vitamin D signaling and IBD. The results showed that in IL‐10 KO mice, the 
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development of IBD symptoms could be accelerated by vitamin D deficiency [40]. Additionally, 
a fulminating form of IBD resulted in ulceration of the intestine and the premature mortality of 
the double VDR and IL‐10 KO mice within a very short time frame (3–5 weeks of age).
Vitamin D receptor knockout or vitamin D‐deficient mice always have T cells deficient that 
have been implicated in the pathology of IBD. Actually, the active form of vitamin D directly 
and indirectly suppresses the function of these pathogenic T cells while inducing several reg‐
ulatory T cells that could suppress IBD progressing [18].
People found that 1, 25(OH)2D and analogs of 1,25(OH)2D could suppress IBD in the IL‐10 KO mice which required adequate dietary calcium, suggesting that 1,25(OH)2D may directly and indirectly control immune function through calcium regulation in vivo. Many evidences 
from multiple different animal models suggested that the increased susceptibility of mice to 
experimental IBD could be caused by vitamin D and VDR deficiency, which could be sup‐
pressed by 1,25(OH)2D [41].
Although at present there has not been a causal relationship between vitamin D status and 
IBD established in the clinic, there have been some clinic reports that show the influence of 
vitamin D in IBD. They found most of children and young adult patients in IBD had low 
vitamin D status (serum 25(OH)D concentration ≤15 ng/mL). Additionally, a randomized, 
controlled clinical trial from November 2007 to June 2010 at the Clinical and Translational 
Study Unit of Children's Hospital in Boston showed that most of the 71 patients (age 5–21) in 
IBD had low vitamin D status in serum (less than 20 ng/mL). A treatment of oral doses of 2000 
IU vitamin D3 daily or 50,000 IU vitamin D2 weekly for 6 weeks could raise serum 25(OH)D 
concentration obviously and the basic conditions of children and adolescents with IBD could 
be improved. The change in serum PTH concentration did not differ [42].
Overall, the available data do suggest that vitamin D status and analogs would be useful for 
normalizing T cell function and in the prevention and treatment of human IBD. But there are 
still many problems that need to be studied, such as which mechanism of the vitamin D medi‐
ated occur in human cells and IBD patients.
3.4. Vitamin D and cancer
Numerous studies have suggested that lower vitamin D level is a risk factor for human can‐
cers, and vitamin D deficiency linked with the incidence and mortality of many types of can‐
cers, including breast, colon, and prostate cancers [43, 44].
Beneficial effects of vitamin D have been observed in experimental cancers induced by various 
chemical carcinogens or genetic mutations, and in studies using human cancer cells implanted 
in nude mice. The anticancer effects of vitamin D included alterations in cell growth, angio‐
genesis, tumor invasion and metastatic potential, and immune surveillance. Many studies 
have demonstrated that vitamin D signaling inhibited the growth of many cancer‐derived cell 
lines in vitro, by inhibiting progression through the cell cycle, inducing apoptosis, and driv‐
ing the cells to a more differentiated phenotype. VDR also played important role in antican‐
cer effect. Some preliminary data suggested that VDR polymorphisms were more frequently 
associated with tumor genes which are Fok1, Bsm1, Taq1, Apa1, EcoRV, and Cdx2 [43–45]. 
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And another study showed that vitamin D receptor expression is linked to potential markers 
of human thyroid papillary carcinoma [46].
Trials in clinic also have shown the potential therapeutic effects of vitamin D in different kinds 
of cancers. For example, in a pilot study of patients with recurrent prostate cancer, oral calcitriol 
(starting with 0.5 mg/day and escalating the maximum dose to 2.5 mg/day) for 6–15 months 
resulted in a significant decrease in the rate of prostate‐specific antigen (PSA) rise during ther‐
apy (in comparison to PSA increase before therapy) in six out of seven patients [43]. In another 
research, scientists provided evidence indicating that vitamin D signaling protected the skin from 
cancer formation by controlling keratinocyte proliferation and differentiation, facilitating DNA 
repair, and suppressing activation of the hedgehog (Hh) pathway following UVR exposure [47].
Although the anticancer effect of vitamin D signaling has been discovered, there are still prob‐
lems that need to be discussed both in experimental and in clinical trials. In vitro and in vivo 
studies have clearly demonstrated the antitumor effects of vitamin D. But the mechanisms of 
antigrowth effects of vitamin D are quite variable in different cell types, and even in different 
cell lines derived from the same type of cancer. In clinic, the results of vitamin D and cancer 
mortality were inconsistent and even oppositive associations. The majority of studies in can‐
cer patients showed that patients with higher vitamin D levels had a decreased risk of mortal‐
ity. But there were some other voice against this. In conclusion, the relationship of vitamin D 
status and anticancer effect is still unclear and warrants further studies.
3.5. Other diseases
There are many more reports and studies about vitamin D and its receptor which were found 
to play crucial role in many fields, such as vitamin D and obstructive sleep apnea in polycystic 
ovary syndrome (PCOS) patients [44], serum 25‐hydroxy vitamin D levels in middle‐aged 
women in relationship to adiposity and height trajectories [48], and vitamin D deficiency 
impairs skeletal muscle function in a smoking mouse model [49]. In engender, vitamin D 
deficiency and low ionized calcium are linked with semen quality and sex steroid levels 
in infertile men [50]. The same result was also found in subfertile women [51]. In cognitive 
behavior, low vitamin D levels were frequent in depression patients, especially 25‐OH D lev‐
els <50 nmol/L were associated with cognitive/affective‐depressive symptoms, and anhedonia 
symptoms in particular [52]. Vitamin D supplementation could prevent depression and poor 
physical function in older adults [53]. Some reports found that the concentration of vitamin 
D in the plasma of patients with metabolic syndrome was significantly lower than its recom‐
mendations [54], and a relationship was detected between vitamin D concentration and expo‐
nents of metabolic syndrome [55, 56]. But a randomized controlled trial for 1 year in a Chinese 
population found that the correction of hypovitaminosis D did not improve the metabolic 
syndrome risk profile [57].
4. Conclusion
It is now well recognized that vitamin D is involved not only in the control of bone health and 
mineral metabolism but also in many other physical progresses, such as the control of immune 
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responses, responses to infectious agents, and cell‐proliferative mechanisms, particularly in 
cancer cells. The vitamin D signaling also exhibits multiple effects, such as anti‐inflammation 
effects, anticancer effect, and cardiovascular‐ and kidney‐protective effects. From a practical 
point of view, vitamin D deficiency participates in many pathological progression and dis‐
eases. In some diseases, the administration of vitamin D or VDRA could rescue the clinical 
symptoms and improve outcomes. In conclusion, vitamin D has many potential therapeutic 
effects and multiple roles in different diseases, physical and pathological progressions, which 
are all worth to be studied further.
Author details
Jia Guo1, 2, 3 and Zhangsuo Liu1, 2, 3*
*Address all correspondence to: zhangsuoliu@sina.com
1  Department of  Nephrology, The First Affiliated Hospital of Zhengzhou University, 
Zhengzhou, Henan, China
2 Nephropathy Research Institutes of Zhengzhou University, Zhengzhou, Henan, China
3  Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 
Zhengzhou, Henan, China
References
[1] Lippi G, Montagnana M, Meschi T, Borghi L. Vitamin D concentration and deficiency 
across different ages  and genders. Aging Clin Exp Res. 2012;24(5):548–51.
[2] Haq A, Svobodová J, Imran S, Stanford C, Razzaque MS. Vitamin D deficiency: a single 
centre analysis of patients from 136 countries. J Steroid Biochem Mol Biol. 2016. pii: 
S0960‐0760(16)30022‐X.
[3] Cashman KD, Dowling KG, Škrabáková Z, Gonzalez‐Gross M, Valtueña J, et al. Vitamin 
D deficiency in Europe: pandemic? Am J Clin Nutr. 2016;103(4):1033–44.
[4] Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25‐hydroxyvitamin D (25‐
OHD) among psychiatric out‐patients in Sweden: relations with season, age, ethnic ori‐
gin and psychiatric diagnosis. J Steroid Biochem Mol Biol. 2010;121(1–2):467–70.
[5] KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treat‐
ment of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD). Kidney Int 
Suppl. 2009;113:S1–130.
[6] Messa P, Alfieri C, Rastaldi MP. Recent insights into vitamin D and its receptor. J 
Nephrol. 2011;24 Suppl 18:S30–7.
A Critical Evaluation of Vitamin D - Basic Overview84
[7] Shab‐Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, Kalayi 
A, et al. Improvement of vitamin D status resulted in amelioration of biomarkers of 
systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev. 
2012;28(5):424–30.
[8] Bikle DD. Vitamin D regulation of immune function. Vitam Horm. 2011;86:1–21.
[9] White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr 
Metab Disord. 2012;13(1):21–9.
[10] Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT. Failure of T cell homing, reduced 
CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vita‐
min D receptor KO mice. Proc Natl Acad Sci U S A. 2008;105(52):20834–9.
[11] Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why 
do T cells have vitamin D receptors? Mol Aspects Med. 2012;33(1):77–82.
[12] Yee YK, Chintalacharuvu SR, Lu J, Nagpal S. Vitamin D receptor modulators for inflam‐
mation and cancer. Mini Rev Med Chem. 2005;5(8):761–78.
[13] Boodhoo N, Sharif S, Behboudi S. 1α,25(OH)2 vitamin D3 modulates avian T lympho‐
cyte functions without inducing CTL unresponsiveness. PLoS One. 2016;11(2):e0150134. 
[14] Shim J, Pérez A, Symanski E, Nyitray AG. The association between serum 25‐hydroxyvi‐
tamin D and human papillomavirus cervicovaginal infection in women in the United 
States. J Infect Dis. 2016. 15;213(12):1886–92.
[15] Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin 
D3 down‐regulates intracellular Toll‐like receptor 9 expression and Toll‐like recep‐
tor 9‐induced IL‐6 production in human monocytes. Rheumatology (Oxford). 
2010;49(8):1466–71.
[16] Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D recep‐
tor‐mediated sequestration of NF‐kappaB signaling. J Am Soc Nephrol. 2008;19(9):1741–52.
[17] Wu S, Sun J. Vitamin D, vitamin D receptor, and macroautophagy in inflammation and 
infection. Discov Med. 2011;11(59):325–35.
[18] Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of 
IL‐17 in the absence of vitamin D signaling. Int Immunol. 2011;23(8):519–28.
[19] Samuel S, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. Nutr Rev. 
2008;66(10 Suppl 2):S116–24.
[20] Xiong M, Gong J, Liu Y, Xiang R, Tan X. Loss of vitamin D receptor in chronic kidney 
disease: a potential mechanism linking inflammation to epithelial‐to‐mesenchymal tran‐
sition. Am J Physiol Renal Physiol. 2012.
The Multiple Roles of Vitamin D Besides Calcium-Phosphorus Metabolism
http://dx.doi.org/10.5772/66643
85
[21] Guo J, Xia N, Yang L, Zhou S, Zhang Q, Qiao Y, Liu Z. GSK‐3β and vitamin D recep‐
tor are involved in β‐catenin and snail signaling in high glucose‐induced epithelial‐ 
mesenchymal transition of mouse podocytes. Cell Physiol Biochem. 2014;33(4):1087–96.
[22] Kumar R, Tebben PJ, Thompson JR. Vitamin D and the kidney. Arch Biochem Biophys. 
2012;523(1):77–86.
[23] Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin 
J Am Soc Nephrol. 2009;4(9):1523–8.
[24] Valdivielso JM, Cannata‐Andia J, Coll B, Fernandez E. A new role for vitamin D receptor 
activation in chronic kidney disease. Am J Physiol Renal Physiol. 2009;297(6):F1502–9.
[25] Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D 
receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol. 
2011;2011:419524.
[26] Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the 
vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73(2):163–71.
[27] Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al. Combination 
therapy with an angiotensin‐converting enzyme inhibitor and a vitamin D analog 
suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 
2007;18(6):1796–806.
[28] Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric 
effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68(6):2823–8.
[29] Klaus G. Renoprotection with vitamin D: specific for diabetic nephropathy? Kidney Int. 
2008;73(2):141–3.
[30] Li YC. Vitamin D and diabetic nephropathy. Curr Diab Rep. 2008;8(6):464–9.
[31] de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective 
vitamin D receptor activation with paricalcitol for reduction of albuminuria in 
patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 
2010;376(9752):1543–51.
[32] Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, et al. Oral cholecal‐
ciferol decreases albuminuria and urinary TGF‐beta1 in patients with type 2 diabetic 
nephropathy on established renin‐angiotensin‐aldosterone system inhibition. Kidney 
Int. 2011;80(8):851–60.
[33] Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of pro‐
teinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney 
Dis. 2012;59(1):67–74.
A Critical Evaluation of Vitamin D - Basic Overview86
[34] Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, et al. Effects 
of vitamin D supplementation on the calcium‐phosphate balance in renal transplant 
patients. Kidney Int. 2009;75(6):646–51.
[35] Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, et al. Vitamin D recep‐
tor agonist doxercalciferol modulates dietary fat‐induced renal disease and renal lipid 
metabolism. Am J Physiol Renal Physiol. 2011;300(3):F801–10.
[36] Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vita‐
min D receptor knockout mice: role of the systemic and cardiac renin‐angiotensin sys‐
tems. Am J Physiol Endocrinol Metab. 2005;288(1):E125–32.
[37] Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin 
D receptor (VDR) in the t‐tubules of cardiac myocytes: VDR knockout cardiomyocyte 
contractility. Endocrinology. 2008;149(2):558–64.
[38] Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D defi‐
ciency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.
[39] Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, et al. Differential 
inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. 
Nephron Physiol. 2007;106(4):76–81.
[40] Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointesti‐
nal immunity in IL‐10 knockout mice. Immunology. 2006;117(3):310–8.
[41] Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch 
Biochem Biophys. 2012;523(1):103–6.
[42] Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip‐Dhima R, DiFabio D, et al. Treatment of 
vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a ran‐
domized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97(6):2134–42.
[43] Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, et al. Prognostic 
role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a 
systematic review. Oncologist. 2011;16(9):1215–27.
[44] Davis CD, Milner JA. Nutrigenomics, vitamin D and cancer prevention. J Nutrigenet 
Nutrigenomics. 2011;4(1):1–11.
[45] Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem 
Biophys. 2012;523(1):107–14.
[46] Izkhakov E, Somjen D, Sharon O, Knoll E, Aizic A, Fliss DM, Limor R, Stern N, Steroid 
J. Vitamin D and obstructive sleep apnea: an unexplored relationship in PCOS patients. 
Biochem Mol Biol. 2016. 53(2):617–8.
[47] Denzer N, Vogt T, Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin can‐
cer: a systematic review. Dermatoendocrinol. 2011;3(3):205–10.
The Multiple Roles of Vitamin D Besides Calcium-Phosphorus Metabolism
http://dx.doi.org/10.5772/66643
87
[48] Lehtinen‐Jacks S, Leu Agelii M, Hunsberger M, Zetterberg H, Lissner L. Serum 25‐
hydroxy vitamin D levels in middle‐aged women in relationship to adiposity and height 
trajectories over three decades. Eur J Clin Nutr. 2016. 70(6):709–14.
[49] Cielen N, Heulens N, Maes K, Carmeliet G, Mathieu C, Janssens W, Gayan‐Ramirez 
G. Vitamin D deficiency impairs skeletal muscle function in a smoking mouse model. J 
Endocrinol. 2016. 229(2):97–108.
[50] Ozgurhan G, Vehapoglu A, Vermezoglu O, Temiz RN, Guney A, Hacihamdioglu B. Risk 
assessment of obstructive sleep apnea syndrome in pediatric patients with vitamin D 
deficiency: A questionnaire‐based study. Medicine (Baltimore). 2016;95(39):e4632.
[51] Lehtinen‐Jacks S, Leu Agelii M, Hunsberger M, Zetterberg H, Lissner L. Serum 
25‐hydroxy vitamin D levels in middle‐aged women in relationship to adiposity and 
height trajectories over three decades. Eur J Clin Nutr. 2016;70(6):709–14.
[52] von Känel R, Fardad N, Steurer N, Horak N, Hindermann E, Fischer F, Gessler K. Vitamin 
D deficiency and depressive symptomatology in psychiatric patients hospitalized witha 
current depressive episode: a factor analytic study. PLoS One. 2015;10(9):e0138550.
[53] de Koning EJ, van Schoor NM, Penninx BW, Elders PJ, Heijboer AC, Smit JH, Bet PM, 
van Tulder MW, den Heijer, van Marwijk HW, Lips P. Vitamin D supplementation 
toprevent depression and poor physical function in older adults: study protocol of the 
D‐Vital study, a randomized placebo‐controlled clinical trial. BMC Geriatr. 2015;15:151.
[54] Godala M, Materek‐Kuśmierkiewicz I, Moczulski D, Szatko F, Gaszyńska E, TokarskiS, 
Kowalski J. Estimation of plasma 25(OH)D vitamin level in patients with metabolicsyn‐
drome. Pol Merkur Lekarski. 2015;39(234):364–7.
[55] Bonakdaran S, Fakhraee F, Karimian MS, Mirhafez SR, Rokni H, Mohebati M, Mazidi 
M, Mousavi M, Ferns GA, Ghayour‐Mobarhan M. Association between serum 25‐
hydroxyvitamin D concentrations and prevalence of metabolic syndrome. Adv Med 
Sci.2016;61(2):219–223. doi: 10.1016/j.advms.2016.01.002.
[56] Kramkowska M, Grzelak T, Walczak M, Bogdanski P, Pupek‐Musialik D, Czyzewska 
K. Relationship between deficiency of vitamin D and exponents of metabolic syndrome.
Eur Rev Med Pharmacol Sci. 2015;19(12):2180–7.
[57] Yin X, Yan L, Lu Y, Jiang Q, Pu Y, Sun Q. Correction of hypovitaminosis D does not 
improve the metabolic syndrome risk profile in a Chinese population: a randomized 
controlled trial for 1 year. Asia Pac J Clin Nutr. 2016;25(1):71–7.
A Critical Evaluation of Vitamin D - Basic Overview88
